All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Tessera Therapeutics Inc., a Cambridge, Mass.-based company working to "write therapeutic instructions into the genome," has raised $230 million in series B financing to back its development of potential cures and treatments for cardiovascular, oncological, neurodegenerative and infectious diseases.